Abstract 14073: Omega-3 Fatty Acid Levels and Risk for Incident Bleeding and Atrial Fibrillation: Multi-Ethnic Study of Atherosclerosis (MESA)

Karan Kapoor,Abdulhamied Alfaddagh,Mahmoud Al Rifai,Deepak L Bhatt,Matthew J Budoff,Khurram Nasir,Michael Miller,Francine K Welty,John W McEvoy,Zeina Dardari,Michael D Shapiro,Roger S Blumenthal,Michael Y Tsai,Michael J Blaha

DOI: https://doi.org/10.1161/circ.142.suppl_3.14073

IF: 37.8

2020-11-17

Circulation

Abstract:Introduction: The association between plasma OM3 FA levels and key safety endpoints identified in the REDUCE-IT trial such as bleeding and atrial fibrillation (AF) remains uncertain. Hypothesis: Consistent with REDUCE-IT, we hypothesized that higher baseline OM3 FA levels, particularly EPA, would be associated with incident bleeding and AF in a population free of clinical ASCVD or AF. Methods: We examined the association between baseline plasma OM3 FA levels (expressed as percent mass of total FA) with incident bleeding and AF in MESA. Bleeding events were identified from review of hospitalization ICD-9/10 codes, and AF from participant report, discharge diagnoses, Medicare claims data, and study ECGs performed at MESA visit 5. Multivariable Cox proportional hazard modeling was used to estimate HRs of the association of continuous OM3 FA (log EPA, log DHA, log (EPA+DHA)) and our outcomes. Results: Among the 6546 participants, mean age was 62.1(±10.2) and 3468(53%) were female. For incident bleeding, consistent statistically significant reductions were seen with increasing levels of EPA and EPA+DHA in unadjusted and adjusted models including medications that modulate bleeding risk, such as aspirin, NSAIDS, corticosteroids and proton pump inhibitors (Table). For incident AF, a significant reduction was seen with increasing levels of DHA in univariate analyses that did not persist following adjustment for AF risk factors. No significant associations were seen with either EPA or EPA+DHA. Conclusions: In MESA, a population free of clinical ASCVD or AF at baseline, higher plasma levels of OM3 FA (EPA and EPA+DHA, but not DHA) were associated with significantly lower risk of hospitalized bleeding events, but there was no significant association with AF. These findings from observational studies will need to be reconciled with clinical trial data of high-dose pharmacologic OM3 FA therapy.

cardiac & cardiovascular systems,peripheral vascular disease